Tumor-specific CRISPR knockouts or point mutants of YBX1, HNRNPA2B1, or ALIX (e.g., SUMO-site variants) could test their roles in exosomal miR-21, miR-200, miR-210 and PD-L1 loading, and the resulting effects on migration, T cell cytotoxicity, and TAM polarization. The gene discussed is HNRNPA2B1; the disease is neoplasm.